CoChat

A Practical Guide to Approaching Biased Agonism at G Protein Coupled Receptors

Open access
Gundry, Jaimee, Glenn, Rachel, Alagesan, Priya, Rajagopal, Sudarshan · 2017 · Frontiers in Neuroscience
Cited by 72

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Biased agonism, the ability of a receptor to differentially activate downstream signaling pathways depending on binding of a “biased” agonist compared to a “balanced” agonist, is a well-established paradigm for G protein-coupled receptor (GPCR) signaling. Biased agonists have the promise to act as smarter drugs by specifically targeting pathogenic or therapeutic signaling pathways while avoiding others that could lead to side effects. A number of biased agonists targeting a wide array of GPCRs have been described, primarily based on their signaling in pharmacologic assays. However, with the promised of biased agonists as novel therapeutics, comes the peril of not fully characterizing and understanding the activities of these compounds. Indeed, it is likely that some of the compounds that have been described as biased, may not be if quantitative approaches for bias assessment are used. Moreover, cell specific effects can result in “system bias” that cannot be accounted by current approach for quantifying ligand bias. Other confounding includes kinetic effects which can alter apparent bias and differential propagation of biological signal that results in different levels of amplification of reporters downstream of the same effector. Moreover, the effects of biased agonists frequently cannot be predicted from their pharmacologic profiles, and must be tested in the vivo physiological context. Thus, the development of biased agonists as drugs requires a detailed pharmacologic characterization, involving both qualitative and quantitative approaches, and a detailed physiologic characterization. With this understanding, we stand on the edge of a new era of smarter drugs that target GPCRs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2017.00017

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • How many drug targets are there?

    Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505 · cited 2×

    “…smarter drugs that target GPCRs. Keywords: G protein coupled receptor, biased agonism, arrestins, G proteins, GRKs INTRODUCTION G protein-coupled receptors (GPCRs) are the most common receptors in the genome and one of the largest drug targets for neuroendocrine disease (Overington et al., 2006).”
    Background
  • A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine

    DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647 · cited 2×

    “These drugs provide analgesia in animal models without the side effects of respiratory depression and tolerance (DeWire et al., 2013; Manglik et al., 2016), and one of these compounds has already shown promise in early phase clinical trials in humans (Soergel et al., 2014).”
    BackgroundMethod

Cited by

See all 72

Metadata

Authors
Gundry, J., Glenn, R., Alagesan, P., & Rajagopal, S.
Venue
Frontiers in Neuroscience
Published
2017-01-24
Volume
11
Pages
17-17
ISSN
1662-453X (ISSN-L)
OpenAlex
W2580073630
Cited by
72
References
2
FWCI
2.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.